Why Vir Biotechnology Stock Skyrocketed Today
Shares of Vir Biotechnology (NASDAQ: VIR) soared 74% on Tuesday after the immunology company released promising results from an early-stage study of its experimental antibody treatment for the hepatitis B virus (HBV).
Preliminary data from Vir Biotechnology's phase 1 trial of its subcutaneously administered monoclonal antibody, VIR-3434, showed a marked reduction in HBV surface antigen levels in patients with chronic HBV infection.
Vir Biotechnology's stock surged on Tuesday. Image source: Getty Images.
Source Fool.com
